Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 110Esophageal Neoplasms 88Neoplasms 68Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 25Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 18Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

Electroporation 2monomethyl auristatin E 1Oxaliplatin 1Gemcitabine 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Pancreatic Cancer × Oxaliplatin × Clear all
NCT02035072 2017-07-21

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
40 enrolled
Gastrointestinal

Unresectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡